$BLUE News Article - bluebird bio Announces EU Conditional Marketing Authorization for ZYNTEGLO(TM) (autologous CD34+ cells encoding ?A-T87Q-globin gene) Gene Therapy for Patients 12 Years and Older with Transfusion-Dependent ?-Thalassemia Who Do Not Have ?0/?0 Genotype
https://marketwirenews.com/news-releases/blue...90084.html